Find disease awareness content and relevant supporting materials

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)By Nancy Lapid(Reuters) -An experimental antibody d

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)By Nancy Lapid(Reuters) -New findings from a Swedis

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)By Nancy Lapid(Reuters) -Hello Health Rounds reader

This ASCO rapid update revises treatment recommendations for patients with stage II/III esophageal carcinoma who have residual disease after neoadjuvant chemoradiotherapy and surgery. It incorporates findings from the CheckMate 577 trial, supporting the use of nivolumab as adjuvant immunotherapy to improve outcomes.

These ASCO guidelines provide detailed recommendations on immunotherapy and targeted therapy for advanced gastroesophageal cancer. Clinicians can find evidence-based strategies for using pembrolizumab and nivolumab for PD-L1 positive tumors, and trastuzumab for HER2-positive tumors. The guidelines also discuss combining these therapies with chemotherapy and highlight the latest research findings to support these protocols.

This ASCO guideline provides evidence-based recommendations for using transoral robotic surgery (TORS) in the multidisciplinary management of oropharyngeal squamous cell carcinoma (OPC). It covers patient selection, HPV status, adjuvant therapy, and the role of TORS in recurrent disease settings.

Read a summary of key oncogene-driven NSCLC clinical trial data, presented by lung cancer experts at WCLC 2025.

Disease information and treatment guidelines

This ASCO guideline provides evidence-based recommendations for managing metastatic clear cell renal cell carcinoma (ccRCC). It covers diagnostic criteria, risk stratification, first-line and subsequent therapies, and considerations for special populations including those with brain or bone metastases.

The ESMO–EURACAN guideline delivers expert recommendations for diagnosing, staging, and treating salivary gland cancers, including parotid, submandibular, sublingual, and minor glands. Developed by a multidisciplinary European team, it integrates scientific evidence with clinical expertise to guide optimal patient care.